Lawyers for both sides in the Tylenol autism MDL lately submitted a joint letter to Judge Cote listing those states where plaintiffs would not have the ability to claim negligent misrepresentation based upon omission. The list included 15 states: Arkansas, California, Colorado, Idaho, Indiana, Kentucky, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, South Dakota, Tennessee, Texas, and Wyoming. Claimants in these states will not have the ability to pursue negligent misrepresentation claims in the litigation, although this will likely have little impact on the ultimate outcome of their cases.
In a joint letter submitted to Judge Cote, the defendants and the plaintiffs in the Tylenol autism MDL have agreed that plaintiffs in certain states will not have the ability to pursue negligent misrepresentation claims based on omissions. The states where these claims are not recognized include: Arkansas, California, Colorado, Idaho, Indiana, Kentucky, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, South Dakota, Tennessee, Texas, and Wyoming. This will probably have little or no influence on the ultimate outcome of the cases.
The makers of Tylenol and generic acetaminophen (also called Paracetamol, its chemical name) are facing numerous product liability lawsuits. These mass tort lawsuits claim the product’s makers and retailers negligently failed to warn expectant women, doctors, and the general public about a potential risk that occurs when the products are used during pregnancy.
Using acetaminophen while pregnant has been linked to a 20% to 30% increase in children diagnosed with autism spectrum disorder (ASD), ADHD (attention deficit disorder), hyperactivity, and other conduct-related disorders. The link between Tylenol and autism is one of the most studied. The dimension of the studies, the regular methodology, and the studies’ designs (described as “robust”) provide solid evidence and a strong argument that paracetamol use during pregnancy results in an increased risk of neurodevelopmental disorder diagnosis in children.
The Tylenol autism lawsuit encompasses all lawsuits filed in Federal Courts throughout the United States against both manufacturers and retailers of generic acetaminophen products and Tylenol. This form of litigation is called Multi-District Litigation (MDL) because it includes potentially victims throughout the country. autism and tylenol against Tylenol and other makers of acetaminophen have been consolidated into a multi-district litigation class action lawsuit. This means all Tylenol lawsuits will be heard in one jurisdiction, even if the plaintiffs are located across the U.S., to consolidate court resources. It also enables plaintiffs to share the burden of expenditures like court costs.
The Tylenol autism lawsuit is attracting nationwide attention. Also referred to as the Acetaminophen Autism Lawsuit, this nationwide lawsuit has the potential to be the biggest mass tort. The Tylenol Autism Lawsuit is a nationwide legal action brought by moms and dads who took Tylenol while pregnant and gave birth to a child diagnosed with autism, ADHD, or other neurodevelopmental disorders. In this article, we share the basic information you require to know to determine if you are eligible for a potential Tylenol-autism claim settlement.
Tylenol autism lawyers for injured parties have to convince a jury that manufacturers like Johnson & Johnson breached their duty of care to consumers by stopping working to warn them of the dangers related to acetaminophen. We believe manufacturers and retailers were both negligent by ignoring a growing body of scientific evidence illustrating acetaminophen use while pregnant increases the risk for autism spectrum disorders. Failing to warn goes to the heart of the Tylenol pregnancy lawsuit.
Judge Cote has accepted allow the defendants to send a consolidated brief on the Daubert challenges to the admissibility the scientific expert evidence existing by the plaintiffs. The plaintiffs had actually submitted a letter asking Judge Cote to deny the request, claiming that the submission of different briefs for each and every individual expert was necessary to ensure a fair outcome. The future of the Tylenol autism class action will hinge on the outcome of the Daubert challenges. If Judge Cote guidelines that the plaintiff’s causation evidence is not admissible in court, every one of the pending cases will eventually get rejected.
